Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China

Xiao-mei Hu; Feng Liu; Rou Ma

doi:10.1007/s11655-010-0506-0

Your Location：

Home >

Browse articles >

Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China

ReviewPaper | Updated：2021-08-27

- Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China
- Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China
- 中国结合医学杂志（英文版） 2010年16卷第4期页码：368-377
- Affiliations：
  
  Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-010-0506-0
  中图分类号：
- 纸质出版日期：2010，
  
  网络出版日期：2010-8-10，
Scan for full text
Hu, Xm., Liu, F. & Ma, R. Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China., Chin. J. Integr. Med. 16, 368–377 (2010). https://doi.org/10.1007/s11655-010-0506-0

Xiao-mei Hu, Feng Liu, Rou Ma. Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China[J]. Chinese Journal of Integrative Medicine, 2010,16(4):368-377.
Hu, Xm., Liu, F. & Ma, R. Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China., Chin. J. Integr. Med. 16, 368–377 (2010). https://doi.org/10.1007/s11655-010-0506-0 DOI：

Xiao-mei Hu, Feng Liu, Rou Ma. Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China[J]. Chinese Journal of Integrative Medicine, 2010,16(4):368-377. DOI： 10.1007/s11655-010-0506-0.

摘要

Chinese arsenic drugs have been applied in Chinese medicine for several centuries. Beginning from 1970s

arsenic containing drugs have been generally used for the treatment of malignant hematologic diseases including acute promyelocytic leukemia

myelodysplastic syndrome

and multiple myeloma. No matter what ingredients of arsenic drugs were applied

either arsenic trioxide

arsenic disulfide

or arsenic containing Chinese herbal compositions including Qinghuang Powder (青黄散) and Realgar-Indigo naturalis formula (复方黄黛片)

they all provided the distinct approaches for the management of malignant hematologic diseases

and good clinical efficacy was obtained with mild adverse reactions. Moreover

the mechanisms of action have been continually elucidated.

Abstract

Chinese arsenic drugs have been applied in Chinese medicine for several centuries. Beginning from 1970s

arsenic containing drugs have been generally used for the treatment of malignant hematologic diseases including acute promyelocytic leukemia

myelodysplastic syndrome

and multiple myeloma. No matter what ingredients of arsenic drugs were applied

either arsenic trioxide

arsenic disulfide

or arsenic containing Chinese herbal compositions including Qinghuang Powder (青黄散) and Realgar-Indigo naturalis formula (复方黄黛片)

they all provided the distinct approaches for the management of malignant hematologic diseases

and good clinical efficacy was obtained with mild adverse reactions. Moreover

the mechanisms of action have been continually elucidated.

关键词

Chinese DrugArsenichematologic diseasesclinical efficacymechanismAdverse Reaction

Keywords

Chinese DrugArsenichematologic diseasesclinical efficacymechanismAdverse Reaction

references

Zhang TD, Li YS. Clinical analysis and empirical study on treatment of Ailing No. 1 in 62 cases of acute promyelocytic leukemia. J Integr Tradit West Med (Chin) 1984;4:19.

Chen G Q, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with down regulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996;88:1052–1061.

Zhang P. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. J Leukemia (Chin) 1999;8:195–196.

Zhang P. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Agents 1999;13:195–200.

Zhang P, Wang SY, Hu LH, Qiu FQ, Yang HF, Xiao YJ, et al. Seven years’ summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide—analysis of 242 cases. J Clin Hematol (Chin) 2000;21:67–70.

Ma J. Targeted thrapy of acute promyelocytic leukemia. China J Cancer (Chin) 1999;8:80.

Ma J, Zhan ZM, Liang H, Gong TJ, Tang QH, Ren S, et al. Effect of arsenic trioxide on the treatment of relapsed/refractory acute promyelocytic leukemia. Oncol Prog (Chin) 2005;3:98–101.

Hu XM, Ma L, Hu NP, Wang ZF, Yang L, Li L, et al. Ailing No. 1 in treating 62 cases of acute promyelocytic leukemia. Chin J Integr Tradit West Med (Chin) 1999;19:473–476.

Sun GZ, Zhu ZQ, Sun JG, Li CL, Liy ZS, Sun PY, et al. Clinical observations on arsenic trioxide (As2O3) in the treatment of 43 cases with acute promyelocytic leukemia. Shandong Tradit Med J (Chin) 2000;40:23.

Guo JM, Liu ZW, Yang J. Use of arsenic trioxide (As2O3) in the treatment of 46 cases with acute promyelocytic leukemia. J Zhengzhou Univ (Med Sci, Chin) 2003;38:797–798.

Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354–3360.

Xu M. Clinical observations on arsenic trioxide (As2O3) in the treatment of relapsed acute promyelocytic leukemia. Acta Univ Med Nanjing (Nat Sci, Chin) 2007;27:873–874.

Bai HQ, Gao P, Zhang Q. Clinical observations on arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia patients relapsed after remission induced by all-trans retinoic acid (ATRA). China Prac Med (Chin) 2008;3:154–155.

Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY. Treatment of acute leukemia with arsenic compounds: in vitro and in vivo studies. Semin Hematol 2001;38:26–36.

Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345–3353.

Liu YF, Shen ZX, Chen X, Wang AH, Cao Y, Zhu YM, et al. Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL). Chin J Hematol (Chin) 2003;24:25–27.

Zhao YZ, Li HQ, Li DP, Li R, Qi JY, Wan CC, et al. Preliminary observation of the combination of arsenic trioxide and all-trans retinoic acid for the treatment of acute promyelocytic leukemia. Chin J Hematol (Chin) 2003;24:32–34.

Feng YQ, He YC, Li Y, Wu JY, Guo Y, Zhang LD, et al. Clinical observation of the treatment with combination of alltrans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia (APL). J Clin Hematol (Chin) 2004;17:294.

Wang JH, Zhang F, Yang YL, Ji SY. Clinical observation of the combination of arsenic trioxide and all-trans retinoic acid for the treatment of acute promyelocytic leukemia. Appl J Gen Pract (Chin) 2004;2:381–382.

Xi YM, Lu XQ, Wang J. Clinical analysis of the combination of arsenic trioxide and all-trans retinoic acid for the treatment of acute promyelocytic leukemia. J Clin Hematol (Chin) 2005;18:109–110.

Chen SQ, Wan DM, Liu YF, Liu LX, Sun L, Sun H. Use of the combination of all-trans retinoic acid and arsenic trioxide (As2O3) in the treatment of 17 cases with acute promyelocytic leukemia (APL). J Leukemia Lymphoma (Chin) 2006;15:131–132.

Ren RF, Feng M. Clinical observation of the combination of arsenic trioxide and all-trans retinoic acid for the treatment of acute promyelocytic leukemia. J Leukemia Lymphoma (Chin) 2006;15:376–377.

Huang ZQ, Xia RX. Preliminary effect observation of the combination of arsenic trioxide and all-trans retinoic acid for the treatment of acute promyelocytic leukemia. Acta Univ Med Anhui (Chin) 2006;41:485–486.

Zhang GC, Zheng D, Li QH, Luo SK, Li J, Peng AH, et al. Effect observation of the combination of arsenic trioxide and all-trans retinoic acid for the treatment of acute promyelocytic leukemia. China J Cancer (Chin) 2004;23:430–434.

Wang GJ, Li W, Cui JW, Gao SJ, Yao C, et al. Therapeutic effects of combination of arsenic trioxide with low-dose all-trans retinoic acid on induction of remission acute promyelocytic leukemia. Natl Med J China (Chin) 2005;85:1093–1095.

Niu JJ, Qu YR. The analysis of curative effect of different treatment regimens in 169 patients with acute promyelocytic leukemia. J Leukemia Lymphoma (Chin) 2006;15:196–197.

He YC, Rong YP, Wu JY, Feng YQ, Zhang HT, Zhao F, et al. Study on the treatment of acute promyelocytic leukemia of all-trans retinoic acid plus arsenic trioxide. J Leukemia Lymphoma (Chin) 2006;15:444–445.

Tao S, Zhou K, Tang DZ, Sun HY, Liu WL, Xu HZ, et al. The significance of combined therapy of arsenic trioxide and alltrans retinoic acid in treating acute promyelocytic leukemia. Chin J Integr Tradit West Med (Chin) 2009;29:111–114.

Jin HS, Lu YX, Mu LX. A comparison analysis of therapeutic effects in treating acute promyelocytic leukemia with all-trans retinoic acid, arsenic trioxide and chemotherapy. China J Modern Med (Chin) 2007;17:1744–1746.

Zhong Z, Liu ZC, Li JW, Cai ZF, Deng XC, Liu P, et al. The clinical observation on arsenic trioxide associated with ATRA in treating acute promyelocytic leukemia for six years. J Clin Hematol (Chin) 2008;21:244–246.

Wang H, Li YC, Liu ZG, Zhang R. Clinical study on arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia. Chin Gen Pract (Chin) 2007;10:804–806.

Zhen T, Chen SJ. Progress on targeted therapy of acute myeloied leukemia with active components of Chinese herbal medicines. Chin J Integr Tradit West Med (Chin) 2009;29:14–18.

Niu C, Yan Hu T, Sun HP, Liu JX, Li XS. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission introduction, 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia. Blood 1999;94:3315–3324.

Yao FS, Zhan Y, Liang H, Yan H, Chen QH, Zhong L, et al. Treatment of acute promyelycytic leukemia with combination of all-trans retinoic acid and arsenic trioxide: a report of 29 cases. Anhui Med Pham J (Chin) 2008;12:957–958.

Ge XY, Yang LH, Wang HW, Ma LM, Qiao ZH. Clinical observations of the treatment with combination of arsenic trioxide (As2O3), all-trans retinoic acid (ATRA) and low dose marcellomycin in acute promyelocytic leukemia (APL). Chin Remed Clin (Chin) 2008;8:70–71.

Li J, Yan M, Ma J. Treatment of acute promyelocytic leukemia of low dose chemotherapy plus arsenic trioxide. J Clin Intern Med (Chin) 2008;25:66.

Chen SJ, Zhao M, Chen Z. Progress of all-trans retinoic acid plus arsenic trioxide in treating active promyelocytic leukemia. Tumor (Chin) 2001;21:415–418.

Huang XJ. Regulation of arsenic trioxide inducing apoptosis. Chin J Hematol (Chin) 1999;20:258–260.

Gao F, Yi J, Shi GY, Jin HF, Shi XG, Tang XM. Cell cyclerelated induction of apoptosis of NB4 cells by arsenic trioxide is associated with difference in reactive oxygen species level in cell cycle. Acta Univ Med Second Shanghai (Chin) 2001;21:296–299.

Liu LX, Du HT, Huang YS, Li HY, Guo CS. Clinical observation of the arsenic trioxide and stanozolol therapy for patients with myelodysplastic syndrome. J Clin Hematol (Chin) 2007;20:334–335.

Liu LX, Mei XX, Zhang QT, Wang F, Ma J. Treatment of arsenic trioxide and stanozolol therapy in 38 cases with myelodysplastic syndrome. J Zhenzhou Univ (Med Sci, Chin) 2008;43:1053–1055.

Liu JX, Chen L, Wang S, Duan LF, Yang YL, Su LJ, et al. Clinical observation on arsenic trioxide associated with ATRA in the treatment of myelodysplastic syndrome. J Leukemia Lymphoma (Chin) 2004;13:96–97.

Li XL, Xue Y, Yang Y, Li S, Wang Y. Clinical observation on arsenic trioxide in treatment of 18 cases with myelodysplastic syndrome. J Leukemia Lymphoma (Chin) 2004;13:300.

Zhang L, Yang J, Guo JM, Zhu ZM, Zhang Y, Zhang LF. Clinical observation on arsenic trioxide in treatment of 22 cases with high risk myelodysplastic syndrome. J Henan Med Univ (Chin) 2001;36:772–773.

Li LP, Liang ZW, Li YQ. Analysis on arsenic trioxide in treatment of 26 cases with myelodysplastic syndrome. Chin J Misdiagn (Chin) 2003;3:1246–1247.

Wu WW, Huang KW, Zhai X. Clinical observation on arsenic trioxide in treatment of 18 cases with myelodysplastic syndrome. Modern Med Sci (Chin) 2008;24:3202–3203.

Ma QJ, Li WP, Zhang HD. Effect of arsenic trioxide combining with ATRA and low dosage chemotherapy in the treatment of myelodysplastic syndrome. J Modern Oncol (Chin) 2005;13:517–518.

Li J, Fu JX, Yuan YQ, Sun Y. Clinical observation on combination of arsenic trioxide and chemotherapy in treatment of myelodysplastic syndrome with excess of blast and transformed RAEB. Shanxi Med J (Chin) 2006;35:644–645.

List AF, Beran M, Dipersio J, Slack J, Vey N, Rosenfeld QS, et al. Opportunities for arsenic trioxide in the treament of myelodysplastic syndromes. Leukemia 2003;17:1499–1507.

Liu YY, Zhai YP, Hou FX, Xi YR, Zhang DS. Effect of arsenic trioxide on myelomonocytic progenitor cells in patients with myelodysplastic syndrome in vitro. J Exp Hematol (Chin) 2008;8:290–293.

Wang W. The effect of arsenic trioxide on MDS line MUTZ-1 cell sline. Jilin Med J (Chin) 2005;26:1262–1264.

Dong HY, Lin F, Xiong H, Cai Z. Inhibition effect of arsenic trioxide on the growth of human MDS cell line MUTZ-1 cells. J Zhejiang Univ (Med Sci, Chin) 2004;33:68–72.

Lu J, Jin J. Mechanisms of arsenic trioxide induced tumor cell apoptosis in myelodysplastic syndrome mice model in vivo. Chin J Pediatr (Chin) 2006;44:782–786.

Yu QH, Zhan R. Progress of arsenic trioxide in treating multiple myeloma. Med Recapitul (Chin) 2005;11:531–533.

Zhang Q, Song ZL. Effect of arsenic trioxide combining with chemotherapy in the treatment of 21 cases with multiple myeloma. J Leukemia Lymphoma (Chin) 2005;14:169–170.

Xu XJ, Guo ZW, He HQ, Lin SH, Shi TH, Ren ZJ, et al. Study on the treatment and prognosis of multiple myeloma: a report of 48 relapsed/refractory cases. J Clin Hematol (Chin) 2005;18:213–215.

Wang Z, Zhao XH, Lu SY, Zhou CH, Xuan M. Effect observation of the combination of arsenic trioxide and thalidomide and vitamin C for the treatment of relapsed/refractory multiple myeloma. J Clin Med Pract (Chin) 2007;11:98–99.

Xiang YS. Clinical efficacy of thalidomide with arsenic trioxide and vitamin C in the treatment of 8 cases with multiple myeloma. Intern Med China (Chin) 2008;3:506–508.

Zhu J, Lu XY. Effect observation of the combination of arsenic trioxide and thalidomide for the treatment of refractory multiple myeloma. China Med (Chin) 2006;1:204–205.

Hu ZP, Lin SY, Luo XS, Shen YP, Shen JP, Zheng ZY. Combination of arsenic trioxide, thalidomide and dexamethasone in treatment for relapsed and refractory multiple myeloma. Bull Chin Cancer (Chin) 2007;16:131–133.

Huang XJ, Zhou YH, Cai X, Shen YL, Jia PM, Yang J, et al. Effects of arsenic trioxide on multiple myeloma cells. China Oncol (Chin) 2000;10:499–501.

Zhu Q, Chen GQ, Huang Y, Shen YL, Cai X, Jia PM, et al. The relationship between sensitivity to arsenic trioxide and antioxidative capacity of malignant hematopoietic cells. Chin J Oncol (Chin) 2000;22:359–361.

Sang YQ. Effect and mechanism of arsenic trioxide in treating multiple myeloma. Shandong Med J (Chin) 2007;47:40–41.

Chen YB, Fu WJ, Hou J, Ding SQ, Wang DX, et al. Effects of arsenic trioxide on cell cycle and expression of cyclin dependent kinase inhibitors of multiple myeloma cells. Chin J Hematol (Chin) 2003;24:193–196.

Zhou AX, Yao BS, Zheng JF. Effect observation of Qinghuang Powder in treating 25 cases with chronic myelocytic leukemia. J Integr Tradit West Med (Chin) 1981;1:16–18.

Zhou AX. Study on treatment of Qinghuang Powder in cases with leukemia. Chin J Integr Tradit West Med (Chin) 1998;18:582–583.

Wang ZX, Zhou AX, Yang L, Yang JM, Hu NP, Wang ZF, et al. Long-term survival more than 10 years of patients with chronic myelocytic leukemia treated with Qinghuang Powder: a report of 6 cases. J Leukemia (Chin) 1998;7:93–94.

Dai XM, Yang XS, Yang WH, Sun PW, Yu ZW. Clinical and experimental studies on traditional Chinese medicine in treating leukemia. Tianjin Tradit Chinese medicine (Chin) 2000;19:56.

Dai XM. Treatment of Liu-Shen Pill in leukemia. Shandong J Tradit Chin Med (Chin) 1999;18:185.

Department of Hematology of Bengbu Medical College. Effect observation of arsenic disulfide in treating chronic myelocytic leukemia for short-term survival. J Bengbu Med Coll (Chin) 1978;1:11.

Wang MC, Guo GL, Liu SX, Zhang JT, Li XM. Effect observation of arsenic disulfide in treating 7 cases with chronic myelocytic leukemia. Shanxi Med J (Chin) 2002;31:152–153.

Chen ZW, Zhou AX, Fu XQ. Observation of clinical outcome and ultramicrostructure for Qinghuang Powder in treating chronic myelocytic leukemia. Chin J Integr Tradit West Med 1994;(Supp):56–58.

Dai XM, Xu F, Guo Y. Experimental study of Liu-Shen-Wan on inducing leukemia cell apoptosis and correlative gene of control apoptosis. Liaoning J Tradit Chin Med (Chin) 2003;30:431–433.

Bai YH, Huang SL. Studies on red orpiment induction of NB4 and HL-60 cell apoptosis. Chin J Hematol (Chin) 1998;19:477–480.

Zhang C, Huang SL, Lu BF, Yu LM, Yang PM. Arsenic bisulfide induces apoptosis in K562 cells. J Dalian Med Univ (Chin) 1998;20:19–20.

Zhou AX, Yao BS, Wang K, Wang TE. Effect observation of Qinghuang Powder in treating acute non-lymphocytic leukemia. Shanghai J Tradit Chin Med (Chin) 1986;2:15.

Huang SL, Guo AX, Xiang Y, Lin HX, Fu L. Clinical study on the treatment of acute promyelocytic leukemia mainly with composite Indigo Naturalis Tablets. Chin J Hematol (Chin) 1995;16:26–27.

Qin SL, Yang K. Effect of composite Indigo Naturalis Tablets in treating acute promyelocytic leukemia. J Clin Hematol (Chin) 1999;12:23.

Xiang Y, Huang SL, Guo AX, Wang QE, Zhang C, Yan JA, et al. The analysis of therapeutic efficiency on treating acute promyelocytic leukemia (APL) with Compound Huangdai Tablets. J Clin Hematol (Chin) 2000;13:11–12.

Kong FS, Cai XJ, Chi CF, Huang SL. The effectiveness of relapsed and refractory acute promyelocytic leukemia treated with Composit Indigo Naturalist Tablets. J Clin Hematol (Chin) 1997;10:103–104.

Lu DP, Wang Q, Liu YF, Wang FR, Jiang B, Liu KY, et al. Advance in the treatment of acute promyelocytic leukemia in China. J Beijing Med Univ (Chin) 2002;34:427–430.

Guan JP, Yuan W, Yang H, Song CL, Wang MC. Clinical study on arsenic disulfide in treating acute promyelocytic leukemia resisted to alltrans retinoic acid. Shanxi Oncol Med (Chin) 2002;10:281–282.

Wang ZX, Zhou AX, Yang L, Chen ZW, Yang JM, Liu F, et al. Effect observation of Qinghuang Powder in treating 7 cases with acute non-lymphocytic leukemia. J Leukemia (Chin) 1999;8:297–299.

Li J, Sun GL, Su H, Chen HR. In vitro study on effect of two different arsenicals on NB4 cells proliferation and programmed cell death. J Leukemia (Chin) 1998;7:136–139.

Liu YF, Jiang B, Lu DP. Study on effects of yellow arsenic on NB-4 cells apoptosis and cell cycle blockage. Chin J Hematol (Chin) 2000;21:647–648.

Zhong L, Chen FY, Han JY, Shao NX, Ouyang RR. Study of expression of PML gene and PML protein in leukemia cells. Acta Univ Med Second Shanghai (Chin) 2001;21:106–109.

Liu H, Qiu JY, Lu DP, Hong B, Shi HL, Shi Y, et al. A serial study of in cytogenetic change and morphology on the tetra-arsenic tetra-sulfide treatment in untreated or recurrent acute promyelocytic leukemia. Chin J Oncol (Chin) 2003;25:163–167.

Zhang C, Huang SL, Xiang Y, Guo AX. Induction of apoptosis by compound “Huangdai” Tablet in acute promyelocytic leukemia. Med J Chin PLA (Chin) 2003;28:556–557.

Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A, 2008;105:4826–4831.

Xu S, Liu F, Ma R. Clinical observation on Qinghuang Powder for treatment of 31 cases of myelodysplastic syndrome. J Tradit Chin Med (Chin) 2006;47:514–515.

Xu S, Hu XM, Xu YG, Yang XH, Wang HZ, Liu F, et al. Effect of treatment for myelodysplastic syndrome by Qinghuang Powder combined with Chinese herbs for reinforcing Shen and strengthening Pi. Chin J Integr Tradit West Med (Chin) 2008;28:216–219.

Gao XX, Wang XQ, Ma JJ. Treatment of arsenic disulfide in 14 cases with myelodysplastic syndrome. J Clin Intern Med (Chin) 1998;5:125.

Xu S, Ma R. Progress of arsenic in treating myelodysplastic syndrome. J Integr Tradit West Med (Chin) 2009;29:83–85.

Yuan HJ, Xu RR, Ding RS, Jiang SH, Lu W. Apoptosis of in vitro cultured BMMNC from MDS patients induced by arsenic sulfide. J Exp Hematol (Chin) 2006;14:276–280.

Wang MC, Liu SX, Li XM. Realgar in the treatment for multiple myeloma. J Clin Hematol (Chin) 2003;16:249–251.

Wang MC, Yang LH, Liu SX, Li XM. Experimental study and clinical application of arsenic disulfide in inducing apoptosis of multiple myeloma cells. Shanxi Med J (Chin) 2002;31:38–39.

Wang MC, Liu SX, Liu PB. Effect of arsenic disulfide on cytogene express spectra in multiple myeloma cell line RPMI8226. J Cent South Univ (Med Sci, Chin) 2006;31:24–27.

FULL TEXT LINK

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Effects of different extracts of kanggushu (抗骨疏) on osteoporosis in model rats and the underlying mechanisms

Antifibrotic effect of the Chinese herbs Modified Danggui Buxue Decoction (加味当归补血汤) on adriamycin-induced nephropathy in rats

Clinical effect of sphenopalatine ganglion needling in treating primary trigeminal neuralgia of liver-yang upsurge syndrome type

Progress in the research of Radix Astragali in treating chronic heart failure: Effective ingredients, dose-effect relationship and adverse reaction

The mechanistic studies of acupuncture and moxibustion in Taiwan